Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)

Trial Profile

Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)

Phase of Trial: Phase II

Latest Information Update: 14 Nov 2018

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms RISE-M
  • Most Recent Events

    • 05 Nov 2018 Status changed from not yet recruiting to recruiting.
    • 01 Nov 2018 Planned initiation date changed from 1 Oct 2018 to 30 Nov 2018.
    • 23 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top